JPM26: Bristol Myers CEO to ‘cast a broad net’ as business development remains a top priority
San Francisco—Bristol Myers Squibb is already aiming to launch more than 10 new medicines by 2030. | Bristol Myers Squibb is already aiming to launch more than 10 new medicines by 2030. But to hear CEO Chris Boerner, Ph.D., tell it, “business development remains a top priority” for the company’s capital allocation strategy heading into 2026.
San Francisco—Bristol Myers Squibb is already aiming to launch more than 10 new medicines by 2030. | Bristol Myers Squibb is already aiming to launch more than 10 new medicines by 2030. But to hear CEO Chris Boerner, Ph.D., tell it, “business development remains a top priority” for the company’s capital allocation strategy heading into 2026.
What's Your Reaction?
:max_bytes(150000):strip_icc()/GettyImages-2187410260-5afe56694791404f99c253dd8d5abe6a.jpg?#)
